Compare FUBO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUBO | GERN |
|---|---|---|
| Founded | 2009 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 928.8M | 753.3M |
| IPO Year | 2020 | 1996 |
| Metric | FUBO | GERN |
|---|---|---|
| Price | $2.60 | $1.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $5.35 | $3.00 |
| AVG Volume (30 Days) | ★ 10.2M | 7.8M |
| Earning Date | 02-27-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $1,616,726,000.00 | $183,403,000.00 |
| Revenue This Year | N/A | $147.42 |
| Revenue Next Year | $4.68 | $39.42 |
| P/E Ratio | $7.76 | ★ N/A |
| Revenue Growth | 1.70 | ★ 522.13 |
| 52 Week Low | $2.28 | $1.04 |
| 52 Week High | $4.90 | $3.12 |
| Indicator | FUBO | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 50.05 |
| Support Level | $2.45 | $1.30 |
| Resistance Level | $2.70 | $1.48 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 61.40 | 13.89 |
FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.